Comparison of different QT correction methods for nonclinical safety assessment in ketamine-anesthetized Indian rhesus monkeys (Macaca mulatta)

• Published in: Toxicology mechanisms and methods Vol. 33; no. 6; pp. 490 - 501
• Main Authors: Bhatt, Laxit K., Shah, Chitrang R., Patel, Rajesh J., Patel, Shital D., Patel, Sudhir R., Patel, Vipul A., Patel, Jitendra H., Dwivedi, Pankaj, Shah, Niraj A., Sundar, Rajesh S., Jain, Mukul R.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 24.07.2023
• Subjects: Cardiovascular safety; electrocardiography; nonclinical; QT correction method; QT prolongation; QT prolongation; Cardiovascular safety; nonclinical; QT correction method; electrocardiography
• ISSN: 1537-6516; 1537-6524
• DOI: 10.1080/15376516.2023.2187730

Rhesus monkeys are a non-rodent species employed in the preclinical safety evaluation of pharmaceuticals and biologics. These nonhuman primate species have been increasingly used in biomedical research because of the similarity in their ionic mechanisms of repolarization with humans. Heart rate and QT interval are two primary endpoints in determining the pro-arrhythmic risk of drugs. As heart rate and QT interval have an inverse relationship, any change in heart rate causes a subsequent change in QT interval. This warrants for calculation of a corrected QT interval. This study aimed to identify an appropriate formula that best corrected QT for change in heart rate. We employed seven formulas based on source-species type, clinical relevance, and requirements of various international regulatory guidelines. Data showed that corrected QT interval values varied drastically for different correction formulas. Equations were compared on their slope values based on QTc versus RR plots. The rank order of the slope for different formulas was (closest to farthest from zero) QTcNAK, QTcHAS, QTcBZT, QTcFRD, QTcVDW, QTcHDG, and QTcFRM. QTcNAK emerged to be the best correcting formula in this study. It showed the least correlation with the RR interval (r = −0.01) and displayed no significant difference amongst the sexes. As there is no universally recognized formula for preclinical use, the authors recommend developing a best-case scenario model for specific study designs and individual organizations. The data from this research will be helpful in deciding an appropriate QT correction formula for the safety assessment of new pharmaceuticals and biologics.